Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Status: Enrolling
Updated:  12/21/2017
Weill-Cornell Medical College
mi
from
New York, NY
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Status: Enrolling
Updated: 12/21/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Status: Enrolling
Updated:  12/21/2017
Mount Sinai Hospital
mi
from
New York, NY
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Status: Enrolling
Updated: 12/21/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Status: Enrolling
Updated:  12/21/2017
Winship Cancer Institute
mi
from
Atlanta, GA
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
A Phase 2 Biomarker Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) Monotherapy to Assess the Association Between NK Cell Status and Efficacy in High Risk Smoldering Myeloma
Status: Enrolling
Updated: 12/21/2017
Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Lebanon, NH
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Morgantown, WV
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Morgantown, WV
Click here to add this to my saved trials
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated:  12/22/2017
mi
from
Vancouver,
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
Status: Enrolling
Updated: 12/22/2017
mi
from
Vancouver,
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Long Beach VA
mi
from
Long Beach, CA
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Long Beach VA
mi
from
Long Beach, CA
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Georgetown University Hospital
mi
from
Washington,
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Miami VA Healthcare System
mi
from
Miami, FL
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Miami VA Healthcare System
mi
from
Miami, FL
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
University of Miami Hospital
mi
from
Miami, FL
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
University of Miami Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Tampa General Hospital
mi
from
Tampa, FL
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Johns Hopkins Medical Center
mi
from
Baltimore, MD
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Johns Hopkins Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated:  12/22/2017
Mount Sinai Hospital
mi
from
New York, NY
Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia
Status: Enrolling
Updated: 12/22/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)
Status: Enrolling
Updated:  12/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant
Renal Allograft Tolerance Through Mixed Chimerism (ITN010ST)
Status: Enrolling
Updated: 12/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
Status: Enrolling
Updated:  12/27/2017
James Graham Brown Cancer Center
mi
from
Louisville, KY
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
Status: Enrolling
Updated: 12/27/2017
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated:  12/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
Phase II Study of Combination Bortezomib (Velcade PS-341) and Rituximab in Patients With Previously Untreated and Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status: Enrolling
Updated: 12/27/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor
Status: Enrolling
Updated:  12/28/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor
Status: Enrolling
Updated: 12/28/2017
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders
Status: Enrolling
Updated:  12/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
In-vivo T-cell Depletion and Hematopoietic Stem Cell Transplantation for Life-Threatening Immune Deficiencies and Histiocytic Disorders
Status: Enrolling
Updated: 12/29/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Tuscaloosa, AL
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
New York, NY
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
Clinical Research Facility
mi
from
Canton, OH
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/2/2018
mi
from
Adelaide,
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/2/2018
mi
from
Adelaide,
Click here to add this to my saved trials
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated:  1/2/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)
Status: Enrolling
Updated: 1/2/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
City of Hope National Medical Center
mi
from
Duarte, CA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Winship Cancer Institute Emory University School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Cleveland Clinic, The
mi
from
Cleveland, OH
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Cleveland Clinic, The
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Charles A. Sammons Cancer Center at Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
University of Utah
mi
from
Salt Lake City, UT
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/3/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
A Safety Study of SGN-CD33A in AML Patients
A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/3/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Tweens to Teens Project at Penn State
"Gender Development in Early Adolescence: Prenatal Hormones and Family Socialization"
Status: Enrolling
Updated:  1/4/2018
The Pennsylvania State University, Dept. of Psychology - Tweens to Teens Project
mi
from
University Park, PA
Tweens to Teens Project at Penn State
"Gender Development in Early Adolescence: Prenatal Hormones and Family Socialization"
Status: Enrolling
Updated: 1/4/2018
The Pennsylvania State University, Dept. of Psychology - Tweens to Teens Project
mi
from
University Park, PA
Click here to add this to my saved trials
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Status: Enrolling
Updated:  1/4/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
Status: Enrolling
Updated: 1/4/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory Menorrhagia
Status: Enrolling
Updated:  1/5/2018
Hemophilia Center of Western PA
mi
from
Pittsburgh, PA
IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Phase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory Menorrhagia
Status: Enrolling
Updated: 1/5/2018
Hemophilia Center of Western PA
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Donor Peripheral Stem Cell Transplant, Fludarabine, and Busulfan in Treating Patients With Hematologic Cancers
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Status: Enrolling
Updated:  1/5/2018
Yale University
mi
from
New Haven, CT
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Status: Enrolling
Updated: 1/5/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Dysregulation of Hematopoiesis in Fanconi Anemia
Status: Enrolling
Updated:  1/8/2018
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
Dysregulation of Hematopoiesis in Fanconi Anemia
Status: Enrolling
Updated: 1/8/2018
Knight Cancer Institute at Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS
Status: Enrolling
Updated:  1/9/2018
Mount Sinai Hospital
mi
from
New York, NY
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Phase I Dose Escalation Study of ON 01910.Na With Increasing Duration of an Initial 3-Day Continuous Infusion in Patients With Refractory Leukemia or MDS
Status: Enrolling
Updated: 1/9/2018
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders
Status: Enrolling
Updated:  1/9/2018
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders
Status: Enrolling
Updated: 1/9/2018
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials